AZD6423 SAD/MAD Study in Healthy Volunteers

Summary

This is a randomized, double-blind, placebo-controlled study of single and multiple ascending dosage levels of AZD6423 in healthy volunteers. The study includes an up to 28-day screening period, an in-house period during which AZD6423 or placebo will be administered IV, and a 4- to 10-day follow-up period after discharge.

Timeline

Start

2013-09

Primary completion

2014-03

Completion

2014-03

Drugs

Indications

No indication recorded.